Find and Pitch Jounalists, Get Your Story Covered

Tags: Alzheimer's disease | Alzheimer’s | biotech | biotechnology | Cancer | drug development | Drug prices | drug pricing | finance | Pharmaceuticals | research | Vaccines biotech pharma Research & Development research-development

	Profile	Recent Articles on Subject
1	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	The clock is ticking, and Cytokinetics is running out of December - 5 months ago BioMarin appeases an activist - 5 months ago STAT+: 3 trends to watch in biotech in 2024 - 5 months ago Tome Biosciences goes public today in another biotech megaround - 5 months ago Carmot’s chance of beating the odds in the biotech market just ended - 6 months ago Flagship Pioneering crosses the pond, opens a European front - 6 months ago STAT+: With biotech in a slump, the industry’s job market is upside down - 6 months ago Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead - 6 months ago The return of biotech’s “bump factor” amid an economic downturn - 6 months ago The apparently strong correlation between biotech stocks and the price of eggs, explained - 6 months ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - 6 months ago BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge - 7 months ago Gene editing has had a big week in the spotlight. Here’s what’s going on - 7 months ago The XBI biotech index hit its lowest point since 2018. No one knows what comes next. - 7 months ago Cell and gene therapies could be a safer bet than other drugs - 7 months ago STAT+: What ever happened to biotech’s big comeback? - 8 months ago
2	Michael Gibney Pharma Voice	Biopharma’s FTC headache deepens with guideline shifts years in the making - 5 months ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - 6 months ago A biotech tackles drug discovery with transcription factor know-how - 6 months ago
3	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The biotech updates you need to read today - 5 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 5 months ago FDA chastens pet companies over antibiotics - 5 months ago The biotech news you missed from the weekend - 5 months ago Novartis is building a new radioligand plant in China - 6 months ago Today’s biotech news roundup, in under 800 words - 6 months ago A new algorithm unveils CRISPR ‘treasure trove’ - 6 months ago These are the need-to-know biotech stories from this weekend - 6 months ago XBI biotech index rises, giving investors a shred of hope - 7 months ago Your Monday morning biotech news roundup - 7 months ago Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO - 7 months ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - 7 months ago Want a biotech buyout? Target cancer - 7 months ago
4	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’ - 5 months ago
5	Christine Hall TechCrunch Writes VC rounds, Daily Crunch. Venture CapitalFoodtechFintech	Food tech roundup: VC funding declines again in Q3 amid fewer deals - 5 months ago
6	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Pfizer plans to depart BIO - 6 months ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 6 months ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - 6 months ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - 7 months ago
8	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: With biotech in a slump, the industry’s job market is upside down - 6 months ago STAT+: Life scientists’ flight to biotech labs stalls important academic research - 6 months ago STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise - 8 months ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - 8 months ago STAT+: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’ - 8 months ago
9	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report - 6 months ago
10	Barbara Ryan Pharmaceutical Executive Pharma analyst, biopharma consultant. Pharma AnalysisConsulting	Reading the Tea Leaves for Biotech As 2024 Approaches - 6 months ago

Journalists covering biotech reporting